Inve India ▾

Accent Microcell share price & results

Accent Microcell· Healthcare

Results to
Sept 2026
Latest analysed call
Q4 FY26
Ownership as of
Sept 2026

Gujarat-based manufacturer of cellulose-based pharmaceutical excipients — MCC, SMCC, CCS and Magnesium Stearate — exported to 75+ countries.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue175 ₹ crore+25.9% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin24.0 %+7.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit31.0 ₹ crore+72.2% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equityUnavailable+0.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.
Free cash flow margin-19.48 %−15.0 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)Unavailable+24.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Guidance

What management said, and what became of it

0 of 2 judged targets kept · 12 open · verdicts reflect calls analysed to Q4 FY26.

Accent Microcell management guidance track record on Inve: 14 targets tracked across analysed earnings calls (0 achieved, 2 missed, 12 open).

TargetOriginal wordingSaidLatest callVerdict
Related Party Transactions (RPT)Negligible level in the near future
Call transcript, Q4 FY25 · 20 May 2025		Q4 FY25Q4 FY26:The topic of RPT was not mentioned or discussed during the earnings call.
Call transcript, Q4 FY26 · 16 May 2026		Ghosted
Unit 3 Phase 1 Commercial Production StartSeptember to October 2025
Call transcript, Q4 FY25 · 20 May 2025		Q4 FY25Q4 FY26:Delayed significantly due to regulatory issues; new target is by June 25th, 2026.
Call transcript, Q4 FY26 · 16 May 2026		Delayed
Unit 3 Premium Products Margin25% on a bottom-line basis
Call transcript, Q4 FY25 · 20 May 2025		Q4 FY25Q4 FY26:Management guided for a 2-3 percentage point increase in blended profit margins going forward, driven by premium products. High realization figures for new products support the high-margin thesis.
Call transcript, Q4 FY26 · 16 May 2026		On Track

Source: Inve Guidance Tracker for Accent Microcell · to Q4 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Accent Microcell's 14 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 11 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹640.8 −3.24% · −₹21.45

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +136.0% 1Y

₹300₹400₹500₹600₹700Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q4 FY26 — 15 May 2026

1Y: ₹271.55 on 24 Oct 2025 → ₹640.8. High ₹725.75 (11 Sept 2026), low ₹266 (29 Oct 2025).

Previous close
₹662.25
Market cap
₹1.6k Cr
52-week range
₹266 – ₹725.75
One year
+136.46%
Price to earnings (FY ending Mar 2026)
36.11×
Return on equity (FY ending Mar 2026)
18.68%

Overview

Symbol
NSE:ACCENTMIC
Exchange
NSE
Currency
INR

What Accent Microcell does

Based on the company's own presentations, annual report and earnings calls.

Accent Microcell manufactures pharmaceutical excipients with a focus on cellulose-based products, including Microcrystalline Cellulose (MCC), Silicified MCC (SMCC), MCC Spheres, Croscarmellose Sodium (CCS), Magnesium Stearate and Powdered Cellulose, sold under the Accel, Acrocell, Maccel and Vincel brands. It runs manufacturing facilities at Pirana (Ahmedabad) and Dahej SEZ in Gujarat, with a third unit being commissioned at Nayka (Kheda) to add value-added products such as CCS, CMC and Sodium Starch Glycolate. Its excipients feed pharmaceutical, nutraceutical, food/bakery/dairy, cosmeceutical and personal-care manufacturers, with a majority of revenue coming from exports across 75+ countries.

Segments

  • Microcrystalline Cellulose (MCC)
  • Silicified Microcrystalline Cellulose (SMCC)
  • MCC Spheres
  • Croscarmellose Sodium (CCS) and other disintegrants
  • Magnesium Stearate & Powdered Cellulose
Manufacturing units
2 operational (Pirana, Ahmedabad & Dahej SEZ, Gujarat) + Unit III commissioning at Nayka, Kheda
Installed capacity
9,200 MTPA, scaling to 12,000 MTPA with Unit III
Capacity utilisation
100% (Pirana Unit I) / 95% (Dahej Unit II)
Global presence
75+ countries
Product grades
15+ overall (22 MCC grades)
Brands
4 (Accel, Acrocell, Maccel, Vincel)
Founded 2012Headquarters Ahmedabad, Gujarat, India

How the price took the results

close before → close after

Q4 FY26
−2.9%
16 May

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Accent Microcell

Free account: one company. Everything above stays public.

Write why you follow Accent Microcell and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Accent Microcell

Guides on how to read this kind of business and the numbers that matter.